Not available
Quote | Halozyme Therapeutics Inc. (NASDAQ:HALO)
Last: | $52.01 |
---|---|
Change Percent: | -0.31% |
Open: | $51.46 |
Close: | $52.01 |
High: | $52.415 |
Low: | $50.93 |
Volume: | 839,303 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Halozyme Therapeutics Inc. (NASDAQ:HALO)
2024-07-01 10:02:13 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips With the technology sector taking over in 2024, now is a great time to consider the best breakout biotech stocks to buy. Investing in these companies can be risky yet extremely rewarding, w...
2024-06-25 06:36:05 ET More on Halozyme Therapeutics Halozyme Therapeutics: The Story Brightens Halozyme Therapeutics, Inc. (HALO) Q1 2024 Earnings Call Transcript Halozyme Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation Bristol Myers Opdivo...
Message Board Posts | Halozyme Therapeutics Inc. (NASDAQ:HALO)
Subject | By | Source | When |
---|---|---|---|
Addendum: Should the temptation arise, kindly forgo enlightening me | easycomeandgo | investorshub | 04/30/2023 2:11:01 PM |
It is high time for me to (do | easycomeandgo | investorshub | 04/30/2023 1:57:44 PM |
I am not sure what it will take | easycomeandgo | investorshub | 04/28/2023 2:20:54 PM |
By the way, it was the last CFO | Fred Kadiddlehopper | investorshub | 04/28/2023 1:49:36 PM |
Yes, the efgartigimod delay was noted here; not | Fred Kadiddlehopper | investorshub | 04/28/2023 1:44:49 PM |
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis PR Newswire OCREVUS ® subcutaneous (SC) injection offers a new 10-minute administration with comparable effica...
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy PR Newswire VYVGART® Hytrulo is the first and only neonatal Fc receptor (FcRn) blocker that is delivered as...